Drug Information and Pharmacotherapy

DI-078

ECONOMIC IMPACT EVALUATION OF OSELTAMIVIR ADJUSTMENT CRITERIA IN RENAL IMPAIRMENT

DI-077

EFFECTIVENESS AND SAFETY OF BIOSIMILAR INFLIXIMAB IN ULCERATIVE COLITIS

DI-075

EVALUATION OF THE EFFECTIVENESS AND SAFETY OF PIRFENIDONE AND NINTEDANIB IN IDIOPATHIC PULMONARY FIBROSIS

DI-073

EXCIPIENTS IN PATIENTS WITH HEREDITARY FRUCTOSE INTOLERANCE

DI-071

INVITRO COMPARISON OF ANTACID DRUGS: APPLICATION TO SIX MARKETED FORMULATIONS

DI-069

COMPLIANCE OF ADOLESCENTS TO THE TREATMENT OF ACNE VULGARIS

DI-068

CHROMATOPSIA AND NIGHT BLINDNESS IN A PATIENT ON CAPECITABINE AND TEMOZOLOMIDE

DI-067

ANALYSIS OF THE USE OF TERIFLUNOMIDE IN A TERTIARY HOSPITAL

DI-066

PERMEATION ENHANCERS: EXCIPIENTS TO BE CONSIDERED IN TOPICAL FORMULATIONS WITH SYSTEMIC ADVERSE EFFECTS

DI-064

STUDY CONCERNING ADVERSE DRUG REACTIONS IN ADULT PATIENTS FROM SURGICAL WARDS IN A CLINICAL EMERGENCY HOSPITAL

DI-063

SURVIVAL BENEFIT WITH VEMURAFENIB IN ‘BRAF’ MUTATION POSITIVE MELANOMA: AREA UNDER THE CURVE BASED REANALYSIS

DI-062

SUSTAINED VIROLOGIC RESPONSE RATES OF NEW DIRECT ACTING ANTIVIRAL AGENTS FOR HCV

DI-060

TRANSLATING INTO ENGLISH A NEW TOOL TO GUIDE DEPRESCRIBING: A CROSS CULTURAL ADAPTATION

DI-059

USE OF DIMETHYL FUMARATE IN A TERTIARY HOSPITAL

DI-058

USE OF OMALIZUMAB IN A TERTIARY LEVEL HOSPITAL

Pages